Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Development of donepezil-induced hypokalemia following treatment of cognitive impairment

  • Kim, Dongryul (Division of Nephrology, Department of Internal Medicine, Incheon St. Mary‘s Hospital, The Catholic University of Korea) ;
  • Yoon, Hye Eun (Division of Nephrology, Department of Internal Medicine, Incheon St. Mary‘s Hospital, The Catholic University of Korea) ;
  • Park, Hoon Suk (Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary‘s Hospital, The Catholic University of Korea) ;
  • Shin, Seok Joon (Division of Nephrology, Department of Internal Medicine, Incheon St. Mary‘s Hospital, The Catholic University of Korea) ;
  • Choi, Bum Soon (Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary‘s Hospital, The Catholic University of Korea) ;
  • Kim, Byung Soo (Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary‘s Hospital, The Catholic University of Korea) ;
  • Ban, Tae Hyun (Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary‘s Hospital, The Catholic University of Korea)
  • Received : 2020.04.11
  • Accepted : 2020.05.14
  • Published : 2021.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.

Keywords

References

  1. Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant 2007;22:3471-7. https://doi.org/10.1093/ndt/gfm471
  2. Widodo D, Setiawan B, Chen K, Nainggolan L, Santoso WD. The prevalence of hypokalemia in hospitalized patients with infectious diseases problem at Cipto Mangunkusumo Hospital, Jakarta. Acta Med Indones 2006;38:202-5.
  3. Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol 2011;7:75-84. https://doi.org/10.1038/nrneph.2010.175
  4. Paltiel O, Salakhov E, Ronen I, Berg D, Israeli A. Management of severe hypokalemia in hospitalized patients: a study of quality of care based on computerized databases. Arch Intern Med 2001;161:1089-95. https://doi.org/10.1001/archinte.161.8.1089
  5. Li HC, Luo KX, Wang JS, Wang QX. Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: a case report. Medicine (Baltimore) 2020;99:e19443. https://doi.org/10.1097/MD.0000000000019443
  6. Arai H, Hashimoto N, Sumitomo K, Takase T, Ishii M. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Japan-Great Outcome of Long-term trial with Donepezil (J-GOLD). Psychogeriatrics 2018;18:402-11. https://doi.org/10.1111/psyg.12340
  7. Cubeddu LX. Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev 2016;12: 141-54. https://doi.org/10.2174/1573403X12666160301120217
  8. Manzo C, Putignano S. Drug-induced lupus erythematosus associated with donepezil: a case report. Age Ageing 2015;44:1062-3. https://doi.org/10.1093/ageing/afv123
  9. US Food and Drug Administration (FDA). Highlights of prescribing information: Aricept [Internet]. Silver Spring (MD): FDA; 2012 [cited 2020 Feb 20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf.
  10. eHealthMe. Will you have hypokalemia with Donepezil? (a study of FDA data) [Internet]. eHealthMe; 2020 [cited 2020 Feb 20]. https://www.ehealthme.com/ds/donepezil/hypokalemia/.
  11. Li XL, Hu N, Tan MS, Yu JT, Tan L. Behavioral and psychological symptoms in Alzheimer's disease. Biomed Res Int 2014;2014:927804. https://doi.org/10.1155/2014/927804
  12. Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol 2005;1:527-36. https://doi.org/10.1517/17425255.1.3.527
  13. Dunn NR, Pearce GL, Shakir SA. Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol 2000;14:406-8. https://doi.org/10.1177/026988110001400410
  14. Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer's disease. Br J Clin Pharmacol 2004;58(Suppl 1):1-8. https://doi.org/10.1111/j.1365-2125.2004.01848.x
  15. Tabish M, Mahendran M, Ray A, Vikram NK. Colistin-induced acquired Bartter-like syndrome: an unusual cause of meltdown. BMJ Case Rep 2020;13:e232630. https://doi.org/10.1136/bcr-2019-232630
  16. Min HK, Kim EO, Lee SJ, Chang YK, Suh KS, Yang CW, et al. Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis. BMC Nephrol 2013;14:13. https://doi.org/10.1186/1471-2369-14-13

Cited by

  1. Thymus vulgaris Essential Oil Protects Zebrafish against Cognitive Dysfunction by Regulating Cholinergic and Antioxidants Systems vol.9, pp.11, 2021, https://doi.org/10.3390/antiox9111083